Your browser doesn't support javascript.
loading
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Yuan, Yuan; Egelston, Colt; Colunga Flores, Oscar; Chaurasiya, Shyambabu; Lin, David; Chang, Helen; Chong, Leslie Mi Ok; Seiz, Amanda; Shah, Monil; Meisen, W Hans; Tang, Aileen; Martinez, Norma; Pickett, Wichanee; Murga, Mireya; Yost, Susan E; Stewart, Daphne; Zhang, Jianying; Ede, Nicholas; Modi, Badri; Kessler, Jonathan; Rand, Jamie; Fong, Yuman.
Afiliación
  • Yuan Y; Cedars-Sinai Medical Center, 127 S San Vicente Blvd, Los Angeles, CA 90048, USA.
  • Egelston C; Department of Immune-Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
  • Colunga Flores O; Department of Immune-Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
  • Chaurasiya S; Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
  • Lin D; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Chang H; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Chong LMO; Imugene Limited, Sydney, NSW, Australia.
  • Seiz A; Imugene Limited, Sydney, NSW, Australia.
  • Shah M; Imugene Limited, Sydney, NSW, Australia.
  • Meisen WH; Department of Translational Development, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Tang A; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Martinez N; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Pickett W; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Murga M; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Yost SE; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Stewart D; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Zhang J; Department of Statistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Ede N; Imugene Limited, Sydney, NSW, Australia.
  • Modi B; Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
  • Kessler J; Department of Radiology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Rand J; Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
  • Fong Y; Department of Surgery, City of Hope Comprehensive Cancer, Duarte, CA, USA.
Ther Adv Med Oncol ; 15: 17588359231210675, 2023.
Article en En | MEDLINE | ID: mdl-38028143
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido